| Literature DB >> 30430779 |
Zhou Liu1,2, Yi Gu1, Xin Li2, Yanyan Liu1,3, Ying Ye1,3, Shihe Guan4, Jiabin Li1,3,5.
Abstract
BACKGROUND: Carbapenem-resistant hypervirulent (hypermucoviscous) Klebsiella pneumoniae (CR-HMKP) poses a significant public health challenge. We investigated its epidemiology and molecular characteristics in a tertiary care hospital in eastern China.Entities:
Keywords: Carbapenem-resistant; Epidemiology; Hypermucoviscous; Hypervirulent; Klebsiella pneumoniae; Molecular characteristics; NDM-1
Mesh:
Substances:
Year: 2019 PMID: 30430779 PMCID: PMC6240523 DOI: 10.3343/alm.2019.39.2.167
Source DB: PubMed Journal: Ann Lab Med ISSN: 2234-3806 Impact factor: 3.464
Clinical and demographic characteristics of the patients with CR-HMKP isolates
| No. Case* | Sex/Age (yr) | Ward | Admission (month-yr) | LOS/LOS in ICU (day) | Underlying disease | Invasive treatment† | Septic shock/Tmax (℃) | Antimicrobial treatment‡ | Outcome |
|---|---|---|---|---|---|---|---|---|---|
| KPN11 | F/63 | NEU-ICU | 10-2013 | 42/42 | Encephalon injury, Pneumonia | Surgery, MV, CVC | No/39.8 | TGC, FOS | Death |
| KPN18 | F/80 | GS-ICU | 11-2013 | 36/11 | Esophageal cancer | MV | No/39.3 | TGC | Death |
| KPN19 | M/42 | ES-ICU | 11-2013 | 39/27 | Severe acute pancreatitis | MV, CVC | Yes/40.8 | MEM | Death |
| KPN34 | F/69 | EICU | 04-2015 | 12/0 | Pneumonia, Diabetes | MV | No/37.9 | TGC, MNO | Discharge |
| KPN53 | M/70 | HS-ICU | 05-2016 | 43/2 | Hepatocellular carcinoma | Surgery | No/38.5 | LVX, SCF | Discharge |
| KPN60 | F/38 | GO-ICU | 07-2016 | 18/2 | Postpartum hemorrhage | Surgery, MV | No/37.9 | LVX | Discharge |
| KPN63 | M/62 | GE-ICU | 07-2016 | 11/10 | Pneumonia | Surgery, CVC | Yes/39.0 | LVX, AMK | Death |
| KPN68 | M/11 | PS | 07-2016 | 49/0 | Scar contracture | Surgery | No/36.6 | LVX | Discharge |
| KPN69 | M/49 | GS-ICU | 07-2016 | 26/2 | Arterial aneurysm | Surgery | No/37.3 | LVX, FOS | Discharge |
| KPN72 | F/60 | EM-ICU | 07-2016 | 6/5 | Thermoplegia, MOF | MV, CVC | Yes/39.3 | LVX | Death |
| KPN74 | F/60 | NEP-PS | 06-2016 | 75/0 | CKD, Diabetes, Gangrene | Surgery, CVC | No/38.6 | LVX | Discharge |
| KPN100 | M/73 | GS-ICU | 06-2017 | 20/19 | Severe acute pancreatitis | MV, CVC | Yes/39.8 | TGC | Death |
| KPN104 | M/42 | ORT-ICU | 06-2017 | 174/7 | Pelvic fractures | Surgery, BC | No/39.0 | TGC, FOS, MEM | Discharge |
*All cases were assessed as hospital-acquired infections; †Invasive treatment prior infection with CR-HMKP; ‡Antimicrobial treatment after CR-HMKP was identified.
Abbreviations: AMK, amikacin; BC, bladder catheter; CKD, chronic kidney diseases; CR-HMKP, carbapenem-resistant hypervirulent (hypermucoviscous) Klebsiella pneumoniae; CVC, central venous catheter; EICU, emergency intensive care unit; EM, emergency medicine department; ES, emergency surgery department; F, female; FOS, fosfomycin; GE, gastroenterology department; GO, gynecology and obstetrics department; GS, general surgery department; HS, hepatobiliary surgery department; ICU, intensive care unit; LOS, length of stay; LVX, levofloxacin; M, male; MEM, meropenem; MV, mechanical ventilation; NEP, nephrology department; NEU, neurosurgery department; ORT, orthopedics department; PS, plastic surgery department; SCF, cefoperazone-sulbactam; TGC, tigecycline; Tmax, maximal body temperature.
Antimicrobial susceptibility testing result of CR-HMKP isolates
| Isolate | SPE | MIC of antimicrobial agents (μg/mL) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AMP | AMK | ATM | CAZ | CIP | COL | CRO | CZO | ETP | FEP | GEN | IPM | LVX | MEM | SXT | TGC | TOB | TZP | ||
| KPN11 | SP | > 256 | 64 | > 128 | 64 | > 32 | 1 | > 32 | > 256 | > 32 | 64 | 16 | > 32 | > 64 | > 32 | 2/38 | 0.50 | 32 | 512 |
| KPN18 | SP | > 256 | 32 | > 128 | > 128 | > 32 | 1 | > 32 | > 256 | > 32 | 64 | 8 | > 32 | > 64 | > 32 | 2/38 | 0.50 | 8 | 512 |
| KPN19 | BL | > 256 | 32 | > 128 | 128 | > 32 | 2 | > 32 | > 256 | > 32 | > 128 | 8 | > 32 | > 64 | > 32 | 2/38 | 0.50 | 16 | > 512 |
| KPN34 | SP | > 256 | 256 | > 128 | > 128 | > 32 | 2 | > 32 | > 256 | > 32 | 64 | 64 | > 32 | > 64 | > 32 | 2/38 | 0.25 | 64 | 256 |
| KPN53 | PU | > 256 | 1 | 1 | > 128 | 1 | 1 | > 32 | > 256 | > 32 | 16 | 0.5 | > 32 | 1 | > 32 | 1/19 | 0.50 | 1 | 256 |
| KPN60 | SE | > 256 | 1 | 2 | > 128 | 2 | 2 | > 32 | > 256 | > 32 | 16 | 0.5 | > 32 | 1 | > 32 | 1/19 | 0.50 | 1 | 256 |
| KPN63 | SP | > 256 | 1 | 2 | > 128 | 1 | 1 | > 32 | > 256 | > 32 | 16 | .0.5 | > 32 | 1 | > 32 | 1/19 | 0.50 | 1 | 256 |
| KPN68 | SE | > 256 | 2 | 1 | > 128 | 1 | 1 | > 32 | > 256 | > 32 | 16 | 1 | > 32 | 1 | > 32 | 1/19 | 0.50 | 1 | 256 |
| KPN69 | PU | > 256 | 1 | 2 | > 128 | 1 | 1 | > 32 | > 256 | > 32 | 16 | 0.5 | > 32 | 1 | > 32 | 1/19 | 0.50 | 1 | 256 |
| KPN72 | SE | > 256 | 2 | 2 | > 128 | 2 | 1 | > 32 | > 256 | > 32 | 16 | 1 | > 32 | 2 | > 32 | 1/19 | 0.50 | 1 | 256 |
| KPN74 | SE | > 256 | 1 | 2 | > 128 | 1 | 2 | > 32 | > 256 | > 32 | 16 | 0.5 | > 32 | 1 | > 32 | 1/19 | 0.50 | 1 | 256 |
| KPN100 | PF | > 256 | > 512 | 64 | 64 | > 32 | 2 | > 32 | 128 | 16 | 8 | > 128 | 8 | 32 | 8 | 4/76 | 1 | > 128 | 128 |
| KPN104 | BL | > 256 | > 512 | 64 | 128 | > 32 | 2 | > 32 | 128 | 16 | 8 | > 128 | 16 | 64 | 8 | 4/76 | 1 | > 128 | 128 |
| RR (%) | 100.0 | 30.8 | 46.2 | 100.0 | 46.2 | 0.0 | 100.0 | 100.0 | 100.0 | 84.6 | 30.8 | 100.0 | 46.2 | 100.0 | 15.4 | 0.00 | 38.5 | 100.0 | |
Abbreviations: AMP, ampicillin; AMK, amikacin; ATM, aztreonam; BL, Blood; CAZ, ceftazidime; CIP, ciprofloxacin; COL, colistin; CRO, ceftriaxone; CZO, cefazolin; ETP, ertapenem; FEP, cefepime; GEN, gentamicin; IPM, imipenem; LVX, levofloxacin; MEM, meropenem; MIC, minimum inhibitory concentrations; PF, puncture fluid; PU, Pus; RR, resistant rate; SE, secretion; SP, sputum; SPE, specimen; SXT, trimethoprim-sulfamethoxazole; TGC, tigecycline; TOB, tobramycin; TZP, piperacillin-tazobactam.
Fig. 1Pulse-field gel electrophoresis (PFGE) dendrograms, genotype, serotype, resistance and virulence genes of the CR-HMKP isolates. The isolates that exhibited PFGE dendrograms with more than 90% similarity are considered one pulsotype (PT). *The isolation date is listed as month-day-year; †Only partial results are shown. Of the other virulence genes tested, entB, iucA, kfuBC, mrkD, rmpA2, ureA, wabG, ybtS, and ycfM were detected in all isolates, and the magA gene was not detected in any of them.
Abbreviations: Aer, aerobactin; KPC, Klebsiella pneumoniae carbapenemase; NDM, New Delhi metallo-β-lactamase; ST, sequence type.
Fig. 2Serum killing assays of the tested isolates. Data are presented as mean±SE, and log10-transformed values were utilized to normalize the data (N=3 for each isolate).
Abbreviations: H-control, hypervirulence control; L-control, low-virulence control; Lg, log10 -transformed values.
Fig. 3Survival curves for G. mellonella larvae inoculated with 1×107 (A), 1×106 (B), 1×105 (C), and 1×104 (D) colony-forming units of the tested isolates, and the data shown are from a single representative experiment out of three repeats. *The curves of KPN11, KPN18, KPN34, KPN100, KPN49L-control and negative control are completely overlapping.
Abbreviations: H-control, hypervirulence control; L-control, low-virulence control.
lgLD50 values of tested isolates in G. mellonella at 72 hours post-infection
| Isolate | lgLD50* |
|---|---|
| KPN11 | 5.38 ± 0.06 |
| KPN18 | 5.51 ± 0.09 |
| KPN34 | 5.44 ± 0.03 |
| KPN53 | 4.95 ± 0.06† |
| KPN100 | 5.61 ± 0.10 |
| KPN54798H−control | 4.81 ± 0.11 |
| KPN49L−control | 5.97 ± 0.14 |
*Data are presented as mean±SD; †The lgLD50 value of KPN53 did not differ from that of KPN54798H-control (P=0.059 by the one-sample t-test) and is significantly lower than those of the other CR-HMKP isolates and KPN49L-control (P<0.05 by the one-sample t-test).
Abbreviations: H-control, hypervirulence control; L-control, low-virulence control; lgLD50, Log10 (50% lethal dose).